Skip to Main Content

Results from Tuesday’s presidential election remain unclear — but that didn’t stop a panel of experts from trying to parse the consequences for the pharmaceutical industry.

At a virtual event hosted by the Massachusetts trade group MassBio Thursday, three panelists were skeptical that either potential president would immediately push aggressive drug pricing legislation. But no one assumed the election would end the issue, either.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!